Webinar Week: 2021 Global Biopharmaceutical Industry Trends – A Look Ahead with Frost & Sullivan
The year 2020 has been game-changing. The pandemic left many businesses in an unprecedented state of uncertainty and presented challenges to the biopharmaceutical industry across research & development and manufacturing work streams. How will the multitude of 2020 events shape new growth opportunities to the biopharmaceutical industry uniquely suited to design and develop personalized therapies and vaccines?
Frost & Sullivan’s 2021 Global Biopharmaceutical Industry Trends will be a series of virtual presentations and panel discussions by a select group of speakers who will explain the ways biopharmaceutical companies are changing, and how they will realign their product and process development strategies to ensure they are ready for 2021 and beyond. Join us for 3 days of 60-minute virtual presentations and round table discussions.
Each day’s presentation will be followed by an interactive virtual round table discussion for biopharma industry executives with a view from 2020 to 2021, new product and process innovation & development. We’d love for you to join for the full hour and welcome a conversation on the dozen+ benefits of attending.
Next Generation Biopharmaceutical Manufacturing Platforms
Advancing Bioprocessing through Materials Science
Innovation in bioprocess strategies are enabled by new technologies. 3M™ advanced materials platforms and bioprocess expertise are used to enable process intensification and single use transition through creation of high-performance smart unit operations. In this session we look at how the interface between materials technology and bioprocessing is used to define and to accelerate key trends in the industry.
- Materials science drives innovation in bioprocessing
- Process compression is enabled by smarter unit operations
- Next generation of bioprocessing requires a step change in technology
Modelling the Processes of Future
Elucidating the value of process intensification using computational modeling.
- High product recovery across unit operations facilitate process intensification
- Performance of unit operations directly affects efficiency of the process
- Single use process transition increases flexibility and productivity
Panel Discussion: Designing Efficient and Economical Processes for Futures
Preparing for Next Generation (or Future) of Biopharmaceutical Manufacturing
Leveraging Development to Advance Digital and PAT Technologies in Manufacturing
What’s next in biopharmaceutical manufacturing? In this session, we will discuss key trends in biomanufacturing and what enables them. Acceleration of process development and characterization through digital and PAT technologies. Transition to column free processing. Tacking challenges in manufacturing of emerging modalities in cell and gene therapy. In addition, we uncover how advanced process technology solutions enable new bioprocess strategies.
- Process technology trends for wide range of modalities Gene to Protein
- Ensuring very high performance and robust unit operations leveraging technologies and digital
- Strategic alignment of digital transformation in development with manufacturing objectives can accelerate digital success
3M™ Polisher ST: Enabling transition to column-free polishing AEX unit operation
- Process technologies for wide range of modalities Gene to Protein
- Transition to high performance and robust unit operations across all modalities
- Design new process platform for mAb manufacturing
Dynamic Forces Drive Antibody Purification into the Future
Never have outside forces driven therapeutic antibody (mAb) development as in today’s environment. Contract Development and Manufacturing Organizations (CDMOs) and biotech/pharmaceutical companies face pressures of reduced timelines, higher mAb titers, new modalities, cost-reduction, and regulatory oversight.
These forces are triggering re-evaluation of the standard mAb purification platform for clarification, capture, polishing and formulation. Today’s presentation will focus on solutions addressing the mounting pressures including combining unit operations, designing alternatives to standard column steps and identifying new capture and polishing media.
Panel Discussion: Biopharma for the Future!
Is Biopharma ready for 2021 and beyond?
How 3M responded to the COVID-19 pandemic to help enable production of life-saving vaccines and therapeutics amidst unprecedented demand
How are strategic partners helping Biopharma to re-align their manufacturing strategies for 2021 and beyond? In this session, discover 3Ms organization wide response to the pandemic to prepare biopharmaceutical and other industries to succeed in post pandemic environment.
3Ms Commitment is to be Improving Our Business, Our Planet, and Every Life.
3M has a long-standing commitment to sustainability. It anchors purpose-driven innovation in our products, manufacturing processes and new technologies—and we’re always trying to do more. One of our key strategies for advancing sustainability is the Sustainability Value Commitment, which requires every new product—including the 3M™ Polisher ST—to demonstrate how it drives impact for the greater good.
- How business responded to pandemic
- Lessons learned from COVID-19
- Sustainability imperative for biopharmaceutical companies to face the future
- 3Ms commitment to sustainability
Panel Discussion: Learning From 2020 Sustainability Imperatives for Biopharma and is Biopharma Supply Chain Model is Ready to Face the Future?
Global Manager Biopharma Application Development
Division Vice President – 3M Separation and Purification Sciences Division
Vice President and
Chief Sustainability Officer
Biopharmaceutical Purification Application Engineering Specialist
Joris Van de Velde
Senior Application Engineer Biopharmaceutical Purification
Application Development Specialist
President and Founder
Rick St. John
Head of Digital Sciences
Director, Science & Technology
VP, Pre-Clinical and Process Development
Director, Supplier Management
Vice President – Global Life Sciences